论文部分内容阅读
目的探讨瑞舒伐他汀钙对稳定性冠状动脉斑块的影响。方法确定为稳定性冠状动脉斑块患者127例,分别采用瑞舒伐他汀钙10mg(A组,45例)、20mg(B组,43例)和40mg(C组,39例)治疗6个月,观察治疗前后低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)、超敏C反应蛋白(hsCRP)、坏死核所占百分比及斑块体积的变化。结果与治疗前比较,治疗后三组LDL-C均降低(P<0.05);治疗后,C组HDL-C高于治疗前和A、B两组(P<0.05),hsCRP低于治疗前(P<0.05)。B组和C组治疗后斑块体积较治疗前缩小[(30.69±8.12)mm3 vs.(37.09±12.01)mm3和(24.99±1.01)mm3 vs.(36.47±14.68)mm3](P<0.05)。三组治疗后的坏死核所占百分比均与治疗前相仿(P>0.05)。结论瑞舒伐他汀钙≥20mg/d有明显稳定冠状动脉斑块的作用。瑞舒伐他汀钙40mg/d能明显增加血清HDL-C和降低hsCRP。
Objective To investigate the effect of rosuvastatin calcium on stable coronary plaque. Methods A total of 127 patients with stable coronary plaque were selected and treated with rosuvastatin calcium 10 mg (group A, n = 45), 20 mg (group B, n = 43) and 40 mg (group C, n = 39) The changes of low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C), hsCRP, percentage of necrotic nuclei and plaque volume before and after treatment were observed. Results Compared with those before treatment, the levels of LDL-C in three groups decreased (P <0.05). After treatment, HDL-C in group C was significantly higher than that before treatment and in groups A and B (P <0.05) (P <0.05). Compared with those before treatment, the volume of plaque in group B and group C decreased significantly after treatment ([(30.69 ± 8.12) mm3 vs. (37.09 ± 12.01) mm3 and (24.99 ± 1.01) mm3 vs. (36.47 ± 14.68) mm3] . The percentage of necrotic nuclei in the three groups after treatment was similar to that before treatment (P> 0.05). Conclusion Rosuvastatin calcium ≥ 20mg / d significantly stabilize the role of coronary plaque. Rosuvastatin calcium 40mg / d can significantly increase serum HDL-C and reduce hsCRP.